Antigen array and diagnostic uses thereof
    1.
    发明申请
    Antigen array and diagnostic uses thereof 审中-公开
    抗原阵列及其诊断用途

    公开(公告)号:US20050260770A1

    公开(公告)日:2005-11-24

    申请号:US11094142

    申请日:2005-03-31

    IPC分类号: G01N33/543 G01N33/564

    CPC分类号: G01N33/564

    摘要: A method of diagnosing an immune disease, or a predisposition thereto, in a subject is disclosed. The method comprises determining a capacity of immunoglobulins of the subject to specifically bind each antigen probe of an antigen probe set, wherein the antigen probe set comprises a plurality of antigen probes selected from the group consisting of at least a portion of a cell/tissue structure molecule, at least a portion of a heat shock protein, at least a portion of an immune system molecule, at least a portion of a homopolymeric polypeptide, at least a portion of a hormone, at least a portion of a metabolic enzyme, at least a portion of a microbial antigen, at least a portion of a molluscan antigen, at least a portion of a nucleic acid, at least a portion of a plant antigen, at least a portion of plasma molecule, and at least a portion of a tissue antigen, wherein the capacity is indicative of the immune disease or the predisposition thereto, thereby diagnosing the immune disease, or the predisposition thereto, in the subject.

    摘要翻译: 公开了一种在受试者中诊断免疫疾病或其倾向的方法。 该方法包括确定受试者的免疫球蛋白的能力以特异性结合抗原探针组的每个抗原探针,其中所述抗原探针组包含多个选自下组的抗原探针:至少一部分细胞/组织结构 分子,至少一部分热休克蛋白,至少一部分免疫系统分子,至少一部分均聚多肽,至少一部分激素,代谢酶的至少一部分,至少 一部分微生物抗原,至少一部分软体动物素抗原,至少一部分核酸,至少一部分植物抗原,至少一部分血浆分子和至少一部分组织 抗原,其中所述能力指示免疫疾病或其易感性,从而诊断受试者的免疫疾病或其易感性。

    DNA vaccines encoding heat shock proteins
    2.
    发明申请
    DNA vaccines encoding heat shock proteins 审中-公开
    编码热休克蛋白的DNA疫苗

    公开(公告)号:US20050197306A1

    公开(公告)日:2005-09-08

    申请号:US10994152

    申请日:2004-11-19

    摘要: The present invention is related to recombinant constructs encoding heat shock proteins or active fragments thereof that are effective in treating T cell mediated inflammatory autoimmune diseases by DNA vaccines. The treatment with the recombinant constructs of the present invention provides long-term expression of specific heat shock proteins for fragments thereof. In one embodiment, the present invention is related to a recombinant construct of a nucleic acid sequence encoding HSP60, HSP70 or HSP90. The present invention also is related to a recombinant construct of a nucleic acid sequence selected from amino acids 1-140 of HSP60, amino acids 130-260 of HSP60 and amino acids 31-50 of HSP60. Another aspect of the present invention is related to an active fragment of HSP60 corresponding to amino acids 31-50 of HSP60 effective in treating arthritis.

    摘要翻译: 本发明涉及编码热休克蛋白或其活性片段的重组构建体,其通过DNA疫苗有效治疗T细胞介导的炎性自身免疫疾病。 用本发明的重组构建体进行的治疗提供了对其片段的特异性热休克蛋白的长期表达。 在一个实施方案中,本发明涉及编码HSP60,HSP70或HSP90的核酸序列的重组构建体。 本发明还涉及选自HSP60的氨基酸1-140,HSP60的氨基酸130-260和HSP60的氨基酸31-50的核酸序列的重组构建体。 本发明的另一方面涉及对应于有效治疗关节炎的HSP60的氨基酸31-50的HSP60的活性片段。

    Cd25 Dna Vaccines for Treating and Preventing T-Cell Mediated Diseases
    3.
    发明申请
    Cd25 Dna Vaccines for Treating and Preventing T-Cell Mediated Diseases 审中-公开
    用于治疗和预防T细胞介导的疾病的Cd25 Dna疫苗

    公开(公告)号:US20070274949A1

    公开(公告)日:2007-11-29

    申请号:US10591558

    申请日:2007-06-08

    IPC分类号: A61K48/00 A61K9/127

    CPC分类号: A61K39/0008 A61K2039/53

    摘要: Compositions comprising nucleic acids encoding the α chain of IL-2 receptor (IL-2Ra, CD25), homologs and fragment thereof, are effective in the treatment and prevention of T cell mediated pathologies. Methods are provided for enhancing anti-ergotypic T cell activity in a subject in need thereof, and for treating or preventing T cell mediated pathologies, such as autoimmune disease, inflammatory diseases and graft rejection.

    摘要翻译: 包含编码IL-2受体α链(IL-2Rα,CD25)的核酸,同系物及其片段的组合物在治疗和预防T细胞介导的病理方面是有效的。 提供了用于在有需要的受试者中增强抗细胞型T细胞活性,以及​​用于治疗或预防T细胞介导的病症如自身免疫性疾病,炎性疾病和移植排斥反应的方法。

    Antigen Receptor Variable Region Typing
    4.
    发明申请
    Antigen Receptor Variable Region Typing 审中-公开
    抗原受体可变区域键入

    公开(公告)号:US20070238099A1

    公开(公告)日:2007-10-11

    申请号:US10581913

    申请日:2004-10-25

    摘要: A method of typing a variable region of a specific variant of an antigen receptor chain is disclosed. The method comprises: (a) exposing a probe set to a sense or antisense strand of a polynucleotide encoding at least a portion of the variable region of the specific variant of the antigen receptor chain, wherein the probe set includes a plurality of probe molecules, wherein each probe molecule of the plurality of probe molecules is substantially complementary to a sense or antisense strand of a nucleic acid sequence region of a specific polynucleotide encoding a variant of the antigen receptor chain, the nucleic acid sequence region encoding a specific combination of at least two variable region segments of the antigen receptor chain; and (b) measuring a hybridization of each probe molecule of the plurality of probe molecules with the sense or antisense strand of the nucleic acid sequence region of the polynucleotide encoding at least a portion of the variable region of the specific variant of the antigen receptor chain, thereby typing the variable region of the specific variant of the antigen receptor chain.

    摘要翻译: 公开了一种对抗原受体链的特定变体的可变区进行分型的方法。 该方法包括:(a)将探针组暴露于编码抗原受体链特异性变体的至少一部分可变区的多核苷酸的有义或反义链,其中探针组包括多个探针分子, 其中所述多个探针分子中的每个探针分子基本上与编码抗原受体链变体的特异性多核苷酸的核酸序列区域的有义链或反义链互补,所述核酸序列区编码至少 抗原受体链的两个可变区片段; 和(b)测量多个探针分子的每个探针分子与编码抗原受体链特异变体的可变区的至少一部分的核酸序列区的有义链或反义链的杂交 ,从而键入抗原受体链的特定变体的可变区。

    T-cell vaccination in the treatment of HIV infection
    5.
    发明申请
    T-cell vaccination in the treatment of HIV infection 失效
    T细胞疫苗接种治疗艾滋病毒感染

    公开(公告)号:US20070122877A1

    公开(公告)日:2007-05-31

    申请号:US11290682

    申请日:2005-11-30

    IPC分类号: C12Q1/68 C12P21/06

    摘要: A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided.

    摘要翻译: 基于自体CD4反应性CD8T细胞的富集,本文描述了用于制备用于治疗免疫缺陷型HIV感染患者的T细胞疫苗的方法。 还描述了用于在免疫缺陷型HIV感染中实施T细胞疫苗接种的方案,以及基于本文开发的T细胞疫苗的治疗方法。 最后,还提供了用于制备T细胞疫苗以及实施方案的试剂盒。

    Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
    7.
    发明申请
    Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens 审中-公开
    通过下调对自身抗原的自身免疫反应来治疗系统性红斑狼疮

    公开(公告)号:US20060030524A1

    公开(公告)日:2006-02-09

    申请号:US11179820

    申请日:2005-07-13

    IPC分类号: A61K48/00 A61K38/17

    摘要: Systemic lupus erythematosus (SLE) can be prevented or treated by down-regulating the autoimmune response to the C-terminal-DNA-binding domain of the p53 protein (p53) by an active principle selected from the group consisting of: (i) a peptide of, or comprising, the C-terminal DNA-binding domain of the p53 protein; (ii) a monoclonal antibody (mAb) specific for said domain of p53 (Ab1), and fragments thereof; (iii) an mAb specific for Ab1 (hereinafter Ab2), and fragments thereof; (iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2; (v) a DNA molecule coding for (i) and (iv) of for the variable region of said Ab1 and Ab2 of (ii) and (iii); and (vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR. SLE can also be diagnosed by assaying for antibodies (Ab1) against the C-terminal DNA-binding domain of p53 or antibodies (Ab2) specific to the Ab1 antibodies.

    摘要翻译: 可以通过选自以下的活性成分下调对自身免疫应答p53蛋白(p53)的C末端-DNA结合结构域的自身免疫应答来防止或治疗系统性红斑狼疮(SLE):(i) 或包含p53蛋白的C-末端DNA结合结构域的肽; (ii)对所述p53结构域(Ab1)特异的单克隆抗体(mAb)及其片段; (iii)Ab1(以下称Ab2)特异性的mAb及其片段; (iv)基于所述Ab1或Ab2的重链或轻链的互补决定区(CDR)的肽; (v)编码(i)和(iv)的(ii)和(iii)所述Ab1和Ab2的可变区的DNA分子; 和(vi)特异于(i)至(iv)的T细胞,其片段,T细胞受体(TCR)和包含所述TCR的可变区的肽。 也可以通过测定针对p53的C末端DNA结合结构域的抗体(Ab1)或Ab1抗体特异性抗体(Ab2)来诊断SLE。

    Immunogenic compositions for induction of anti-tumor immunity
    9.
    发明申请
    Immunogenic compositions for induction of anti-tumor immunity 失效
    用于诱导抗肿瘤免疫的免疫原性组合物

    公开(公告)号:US20050208065A1

    公开(公告)日:2005-09-22

    申请号:US11129359

    申请日:2005-05-16

    摘要: The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

    摘要翻译: 本发明涉及在哺乳动物中诱导抗肿瘤免疫和/或诱导对p53的免疫应答的方法。 所述方法包括向哺乳动物施用有效量的选自以下的至少一种免疫原:(i)基于抗p53mAb的重链或轻链的CDR的肽,所述肽能够引发 p53抗体; 和(ii)在合适的基因递送载体中编码抗p53mAb的可变(V)区的DNA分子。 优选地,免疫原以药物组合物的形式施用。 优选地,肽的长度为7至30个氨基酸残基并且包含重链的CDR2或CDR3的序列或抗p53mAb的轻链的CDR3的序列。

    Method for inhibiting heparanase activity
    10.
    发明授权
    Method for inhibiting heparanase activity 失效
    抑制肝素酶活性的方法

    公开(公告)号:US5206223A

    公开(公告)日:1993-04-27

    申请号:US583851

    申请日:1990-09-17

    IPC分类号: C08B37/10

    摘要: Heparanase activity in a patient may be inhibited by administering an effective heparanase-inhibiting amount of heparin or an effective chemically modified derivative of heparin which inhibits heparanase activity. Such derivatives are preferably N-desulfated, N-acetylated heparin or O-desulfated, N-acetylated heparin. By means of this invention, allograft rejection may be prevented or delayed and autoimmune diseases such as arthritis may be alleviated and treated.

    摘要翻译: 可以通过施用抑制肝素酶活性的有效的乙酰肝素酶抑制量的肝素或有效的化学修饰的肝素衍生物来抑制患者中的肝素酶活性。 此类衍生物优选为N-脱硫酸,N-乙酰化肝素或O-脱硫酸,N-乙酰化肝素。 通过本发明,可以预防或延迟同种异体移植排斥反应,并且可以减轻和治疗自身免疫性疾病如关节炎。